Annexon biosciences strengthens leadership team with appointment of jamie dananberg, m.d., as chief medical officer

Brisbane, calif., july 27, 2023 (globe newswire) -- annexon, inc. (“annexon”) (nasdaq: annx), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the appointment of jamie dananberg, m.d., as chief medical officer.
ANNX Ratings Summary
ANNX Quant Ranking